Search
Close this search box.
Register
Healthed-White-on-Blue
Search
Close this search box.

Vaccination

Image_Paul Griffin0
Prof Paul Griffin
Videos iconVideos

Recombinant respiratory syncytial virus pre-fusion F protein vaccine

In this Product Explainer, Infectious Disease Physician and Microbiologist Prof Paul Griffin explains the role of a recombinant respiratory syncytial virus pre-fusion F protein vaccine for prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).

Expert/s: Prof Paul Griffin
Image_A Prof Woodward
A/Prof Michael Woodward AM
Videos iconVideos

Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted

In this Product Explainer Geriatrician A/Prof Michael Woodward AM explains an adjuvanted vaccine indicated for the active immunisation of individuals 60 years and older for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).1

Expert/s: A/Prof Michael Woodward AM
shutterstock_227545147
A/Prof Christopher Blyth
Clinical Articles iconClinical Articles

Babies in WA will soon be immunised against RSV

All WA babies under eight months old, as well as those aged eight to 19 months at increased risk of severe RSV infection, will be eligible for monoclonal antibodies.

Expert/s: A/Prof Christopher Blyth, Prof Allen Cheng
shutterstock_2363802165
Dr Monica Wang
Clinical Articles iconClinical Articles

Health misinformation is rampant on social media

The global anti-vaccine movement and vaccine hesitancy that accelerated during the COVID-19 pandemic show no signs of abating...

Expert/s: Dr Monica Wang
ian-talmacs-MlTXrdhYOdk-unsplash
Lynnette Hoffman
Clinical Articles iconClinical Articles

Three RSV vaccines coming

What we know about the RSV vaccines so far...

Expert/s: Lynnette Hoffman
Image_Paul-Van-Buynder0
Prof Paul Van Buynder
Videos iconVideos

New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Expert/s: Prof Paul Van Buynder
Proud,Mature,Woman,Smile,After,Vaccination,With,Bandage,On,Arm.
Healthed Logo
Learning Modules iconLearning Modules

2023 Influenza Preparedness & Vaccine Options for Older Adults

The 2023 influenza season is expected to start early and be more severe than the last few years. It’s important for front line immunisers to be updated with the latest information, public health advice and practical strategies for this year’s season. Influenza causes a large burden of disease in Australia with sick days, hospitalisation and death. Vaccination is readily available and updated yearly to include the most recent strains. It is widely recommended across the community, but especially for the most vulnerable including the very young, old, Indigenous Australians, and people with underlying comorbidities.

Paul-Griffin
Prof Paul Griffin
Videos iconVideos

Protein based COVID-19 vaccine

In this Product Explainer, Infectious Disease Physician and Clinical Microbiologist A/Prof Paul Griffin explains the recombinant protein nanoparticle COVID-19 vaccine with a proprietary adjuvant, including the mechanism of action, efficacy, and tolerability; and provides an update on boosters, indications, and access (8 mins).

Expert/s: Prof Paul Griffin
AProf John Litt
A/Prof John Litt AM
Videos iconVideos

Influenza vaccines for older adults in the 2023 influenza season

In this Product Explainer, Public Health Physician A/Prof John Litt AM explains the currently funded adjuvanted quadrivalent influenza vaccine for people 65 years and over and how it fits in the 2023 influenza season (6 mins). This product explainer is supported by Seqirus

Expert/s: A/Prof John Litt AM
One,Person,Is,Answering,Question,About,Vaccines.,He,Needs,Meningococcal
Emma Tinning
Clinical Articles iconClinical Articles

Rise in unlinked meningococcal cases: what GPs need to know

Meningococcal B strain is responsible for most recent cases in NSW, but free access to that vaccine is limited

Expert/s: Emma Tinning
Dr Daryl Cheng
A/Prof Daryl Cheng
Videos iconVideos

Invasive meningococcal disease and the MenACWY-TT conjugate vaccine

In this Product Explainer, Paediatrician Dr Daryl Cheng explains the role of the MenACWY-TT conjugate vaccine for invasive meningococcal disease, the importance of adolescent vaccination and opportunistic immunisation, and the healthcare professional’s role in improving uptake rates in this age group (7 mins).

PP-NIM-AUS-0340. May 2023

Expert/s: A/Prof Daryl Cheng
Image_Paul-Van-Buynder0
Prof Paul Van Buynder
Videos iconVideos

Bivalent original/omicron pre-filled syringe for COVID-19 vaccination

In this Product Explainer, Public Health Physician Prof Paul Van Buynder explains the role of the Bivalent Original/Omicron BA.4-5 pre-filled syringe COVID-19 vaccine and provides an update on the situation in aged care, and how boosters can assist in protecting the community against symptomatic infection and severe disease (5 mins).

Expert/s: Prof Paul Van Buynder

Education by clinicians, for clinicians

Get the app

Site

Company

Connect

Legal

Discover

Healthed

CPD platform